Concepedia

Author

Daniel S.W. Tan

National Cancer Centre SingaporeORCID

Also Known As

Anil K. Suri, D S Tan, D S W Tan, D S-W Tan, D SW Tan, D. S. W. Tan, D. Tan, D.S-W. Tan, D.S. Tan, D.S. Weng Tan

508

Publications

17.6K

Citations

55

H-Index

107

Concepts

All Affiliations

National Cancer Centre SingaporeDuke-NUS Medical SchoolNational University of SingaporeSingapore General HospitalGenome Institute of Singapore
DS

About

Daniel S.W. Tan is an author at National Cancer Centre Singapore specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

45

6.3K

2

Health Sciences

8

8

1.3K

3

Engineering

4

4

134

4

Public Health

1

1

15

5

Biomedical Engineering

1

1

13

Daniel S.W. Tan

×

108

Publications

13.1K

Citations

47

H-Index

YearCitations

Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer

Alice T. Shaw, Dong-Wan Kim, Ranee Mehra,

New England Journal of Medicine

2014

1.4K

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Yannick Simoni, Étienne Becht, Michael Fehlings,

Nature

2018

1.3K

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari,

The Lancet

2017

1.1K

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han,

New England Journal of Medicine

2020

957

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson,

New England Journal of Medicine

2020

731

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

King Pan Ng, Axel M. Hillmer, Charles Chuah,

Nature Medicine

2012

550

Genomic landscape of lung adenocarcinoma in East Asians

Jianbin Chen, Hechuan Yang, Audrey Su Min Teo,

Nature Genetics

2020

517

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan,

The Lancet Oncology

2016

467

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim,

The Lancet Oncology

2021

428

Methionine is a metabolic dependency of tumor-initiating cells

Zhenxun Wang, Lian Yee Yip, Jia Hui Jane Lee,

Nature Medicine

2019

380

Page 1